C57BL/6-Atp1a3tm1Stcl/H

Status

Available to order

EMMA IDEM:15262
International strain nameC57BL/6-Atp1a3tm1Stcl/H
Alternative nameB6-Atp1a3 tm1aStcl (a.k.a. Atp1a3-D923Y; MU225)
Strain typeTargeted Mutant Strains : Conditional mutation
Allele/Transgene symbolAtp1a3tm1Stcl
Gene/Transgene symbolAtp1a3

Information from provider

ProviderSteven Clapcote
Provider affiliationSchool of Biomedical Sciences, University of Leeds
Genetic informationA targeting vector consisting of a floxed “loxP-SA-CDS of exon 7~23 (D923Y)-3*polyA-loxP” cassette followed downstream by a “SA-CDS of exon 7~23 (E309D/D923Y)-polyA” cassette was introduced into intron 6 of Atp1a3 by Cyagen Biosciences Inc.
Phenotypic informationHomozygous:
Atp1a3 (or Atp1a3) homozygous mice are neonatal lethal (born alive but do not survive to weaning).

Heterozygous:
Phenotypic analysis is ongoing. However, male Atp1a3 heterozygotes are known to display a 21% decrease in body weight at 4 weeks of age. Heterozygotes of both sexes display a deficit in cued fear conditioning and locomotor hyperactivity in the open field and the Y-maze (unpublished observations).
Breeding historyThe Atp1a3tm1aStcl mutant allele was introduced into TurboKnockout ES cells (derived from the C57BL/6 strain) and has been maintained by backcrossing to the C57BL/6NTac strain. The line is currently maintained by breeding wild-type females from the colony with heterozygous males.
ReferencesNone available
Homozygous fertileno
Homozygous viableno
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreMary Lyon Centre at MRC Harwell, Oxford, United Kingdom

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

IMPC phenotypes (gene matching)
  • decreased anxiety-related response / IMPC
  • hyperactivity / IMPC
  • improved glucose tolerance / IMPC
  • preweaning lethality, complete penetrance / IMPC
  • abnormal locomotor behavior / IMPC
  • increased exploration in new environment / IMPC
MGI phenotypes (gene matching)
  • tremors / MGI
  • paralysis / MGI
  • abnormal temporal lobe morphology / MGI
  • abnormal dentate gyrus morphology / MGI
  • convulsive seizures / MGI
  • decreased body weight / MGI
  • decreased body size / MGI
  • decreased anxiety-related response / MGI
  • ataxia / MGI
  • hyperactivity / MGI
  • hypoactivity / MGI
  • impaired coordination / MGI
  • abnormal gait / MGI
  • short stride length / MGI
  • decreased exploration in new environment / MGI
  • abnormal spatial learning / MGI
  • abnormal startle reflex / MGI
  • abnormal sleep pattern / MGI
  • limb grasping / MGI
  • increased thermal nociceptive threshold / MGI
  • seizures / MGI
  • abnormal motor capabilities/coordination/movement / MGI
  • premature death / MGI
  • abnormal CNS synaptic transmission / MGI
  • abnormal respiratory function / MGI
  • abnormal sensorimotor gating / MGI
  • increased thigmotaxis / MGI
  • abnormal long term object recognition memory / MGI
  • increased susceptibility to pharmacologically induced seizures / MGI
  • astrocytosis / MGI
  • abnormal response to novel object / MGI
  • nervous system phenotype / MGI
  • enhanced coordination / MGI
  • impaired passive avoidance behavior / MGI
  • abnormal neuron physiology / MGI
  • abnormal behavior / MGI
  • dystonia / MGI
  • homeostasis/metabolism phenotype / MGI
  • growth/size/body region phenotype / MGI
  • behavior/neurological phenotype / MGI
  • abnormal action potential / MGI
  • abnormal enzyme/coenzyme activity / MGI
  • abnormal spike wave discharge / MGI
  • abnormal xenobiotic pharmacokinetics / MGI
  • microgliosis / MGI
  • decreased prepulse inhibition / MGI
  • abnormal seizure response to inducing agent / MGI
  • environmentally induced seizures / MGI
  • abnormal miniature inhibitory postsynaptic currents / MGI
  • impaired contextual conditioning behavior / MGI
  • enhanced conditioned place preference behavior / MGI
  • enhanced behavioral response to addictive substance / MGI
  • increased sensitivity to xenobiotic induced morbidity/mortality / MGI
  • abnormal hippocampus granule cell morphology / MGI
  • abnormal hippocampus pyramidal cell morphology / MGI
  • neonatal lethality, complete penetrance / MGI
  • preweaning lethality, incomplete penetrance / MGI
  • abnormal habituation / MGI
  • abnormal habituation to a new environment / MGI
  • abnormal sensitization to xenobiotic / MGI
  • decreased frequency of paradoxical sleep / MGI
  • abnormal paradoxical sleep pattern / MGI
  • abnormal non-rapid eye movement sleep pattern / MGI
  • impaired spatial learning / MGI
  • increased kindling response / MGI
  • prolonged circadian behavior period / MGI

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*
  • Tissue - Types of tissue, service fee and delivery time available upon request

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
MTA will be issued after an order has been submitted.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).